Gilead Sciences posted fourth-quarter results that exceeded Wall Street expectations and forecast 2025 earnings above analyst ...
Gilead Sciences posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% ...
Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.
Gilead Sciences faces revenue growth challenges as its blockbuster drugs lose exclusivity by 2033. Check out my ...
We recently published a list of 10 Best Wide Moat Stocks to Invest In. In this article, we are going to take a look at where ...
Gilead Sciences, Inc. ( NASDAQ: GILD) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...
Gilead Sciences reported its fourth-quarter financial results after Tuesday's closing bell. Here's a look at the highlights ...
Gilead Sciences Inc. hit a new 52-week high, surpassing its previous peak of $99.45, which the company achieved on February ...
AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...
Salesforce on Wednesday said former Gilead Sciences finance chief Robin Washington will join the software maker to become ...
Hosted on MSN4h
Gilead Sciences (NASDAQ:GILD) Delivers Strong Q4 NumbersBiopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported in Q4 CY2024, with sales up 6.4% year on year to $7.57 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results